Why Is Applied Therapeutics (APLT) Stock Down 30% Today?
APLT stock is down on lackluster clinical trial results Applied Therapeutics (NASDAQ:APLT) stock is falling on Friday following the release of Phase 3 clinical trial data from the clinical-stage biopharmaceutical company. This data comes from Applied Therapeutics’ ARISE-HF Phase 3 trial of AT-001…
#aplt #appliedtherapeutics #riccardoperfetti #phd #sglt2 #glp1 #ciso #dermatatherapeutics #drma #williamwhite